VCs realize exit as Pfizer adds RSV therapy via ReViral takeout

The purchase by Pfizer of ReViral for up to $525 million will give the pharma a therapy for RSV and will provide an exit for a VC syndicate that supplied about $120 million to the start-up over three rounds.

Pfizer Inc. (NYSE:PFE) will gain antiviral treatment sisunatovir with its takeout of ReViral Therapeutics Ltd., a Stevenage, U.K.-based company founded in 2011 with U.S. operations in North Carolina. The therapy has already shown reductions in viral load in a Phase II challenge study to treat respiratory syncytial virus among adults, and is in a Phase II trial among infants...